You’ve clearly identified a massive, terrifying problem with Antimicrobial Resistance, which is a good start. But calling it 'transforming' before you've even hit first-in-human trials is a bold claim, even for a biotech.

The market numbers are huge, but your 'fire extinguishers of medicine' graphic belongs in a grade school textbook, not a serious pitch. We need a realistic path to addressing even a fraction of that $33 billion, not just big bubbles.

A >99% gross margin on a proprietary nanoparticle vial? Now you're speaking my language – that's a razor-less razorblade with some serious teeth. Your strategic roadmap also shows actual business acumen, which is rare.

You have solid scientific and medical chops, but listing 'TBD' for your financial lead is an immediate deal-breaker. You can't raise millions without someone who knows how to manage a budget beyond the lab's coffee fund.

Preclinical data and recognition from Nature and the BBC are good for early scientific validation. However, your competitive landscape is so one-sided it looks like you graded your own homework – show some humility and real challenges.

The explanation of your tech was clear, but that new-agey logo looks like it belongs on a yoga mat, not a cutting-edge biotech firm. And as for the fire extinguisher clip art, I have no words.